This growth is fueled by the companies popular weight loss and diabetes drugs, Zepbound and Moinjaro. When discussing its second-quarter results in August, company officials said the two drugs accounted for almost 40% of Eli Lilly’s total sales. Those results caused the company’s stock to rise by 10% on Aug. 8, according to CNBC.
Eli Lilly’s current market value is close to $900 million, as of this writing.
